Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The right program makes you feel informed, supported, and medically cared for from the first consultation onward
Patients and healthcare practitioners are looking for therapies that can be effective while making life convenient and easy at the same time
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
Friendly, positive, and proactive communication
Most patients reach target dose (8-12mg for retatrutide) by week 16-20 and maintain that dose through week 48 with continued efficacy
R.SharmaA.JawedA
US$ 23.93
US$ 25.50
US$ 22.29
US$ 26.01
US$ 23.20
US$ 21.38
